Abemaciclib

Generic Name
Abemaciclib
Brand Names
Verzenio, Verzenios
Drug Type
Small Molecule
Chemical Formula
C27H32F2N8
CAS Number
1231929-97-7
Unique Ingredient Identifier
60UAB198HK
Background

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...

Indication

适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌;⑵或联合氟维司群,二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌;⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。

Associated Conditions
HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
Associated Therapies
-

A Study of Abemaciclib in Recurrent Glioblastoma

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2016-12-05
Last Posted Date
2024-07-16
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
45
Registration Number
NCT02981940
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

and more 4 locations

A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-09-29
Last Posted Date
2020-09-25
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
26
Registration Number
NCT02919696
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

First Posted Date
2016-08-30
Last Posted Date
2019-01-04
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
40
Registration Number
NCT02884089
Locations
🇺🇸

Dallas Clinical Research Unit, Dallas, Texas, United States

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

First Posted Date
2016-08-05
Last Posted Date
2022-11-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
210
Registration Number
NCT02857270
Locations
🇯🇵

National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

🇺🇸

Florida Cancer Specialists, Sarasota, Florida, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 10 locations

Study of Abemaciclib in Dedifferentiated Liposarcoma

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2016-07-27
Last Posted Date
2024-08-02
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
33
Registration Number
NCT02846987
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2016-07-13
Last Posted Date
2018-03-29
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
101
Registration Number
NCT02831530
Locations
🇫🇷

Gustave Roussy, Villejuif, Val De Marne, France

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

First Posted Date
2016-06-07
Last Posted Date
2017-10-31
Lead Sponsor
Eli Lilly and Company
Registration Number
NCT02792725
Locations
🇺🇸

UCLA Medical Center, Santa Monica, California, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Pacific Cancer Care, Monterey, California, United States

and more 7 locations

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

First Posted Date
2016-06-06
Last Posted Date
2024-05-31
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
215
Registration Number
NCT02791334
Locations
🇪🇸

Hospital Madrid Norte Sanchinarro, Madrid, Spain

🇨🇳

National Cheng Kung University Hospital, Tainan, Taiwan

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 11 locations

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

First Posted Date
2016-05-27
Last Posted Date
2020-08-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
94
Registration Number
NCT02784795
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath